Thematic Exposure -- 6.5/10
Church & Dwight is a well-run collection of niche oligopoly positions with strong #1/#2 brands
across several categories -- Arm & Hammer, Trojan, OxiClean, TheraBreath, Hero Cosmetics, and Batiste.
The 2025 portfolio reshaping (divesting VMS/Vitafusion) concentrated the business on higher-quality
positions and reduced private label exposure from ~12% to ~5%. However, the dominant positions are
in individually small TAMs, and in the larger categories (laundry, oral care), CHD competes as a
strong but not dominant player against much larger CPG companies. The thematic story is "steady niche
compounder with M&A optionality" rather than "riding a secular mega-trend."
Weight: 25%
Revenue Mix (FY2025)
| Segment | FY2025 ($M) | FY2024 ($M) | YoY | % of Total |
|---|---|---|---|---|
| Consumer Domestic | $4,774.8 | $4,732.3 | +0.9% | 77.0% |
| Consumer International | $1,129.4 | $1,071.5 | +5.4% | 18.2% |
| Specialty Products (SPD) | $299.0 | $303.3 | -1.4% | 4.8% |
| Total Net Sales | $6,203.2 | $6,107.1 | +1.6% | 100% |
Data sourced from Daloopa.
Consumer International (+5.4%) is the fastest-growing segment, reflecting under-penetration vs. peers.
| Consumer Domestic Product Line | FY2025 ($M) | FY2024 ($M) | YoY | % of Domestic |
|---|---|---|---|---|
| Household Products | $2,556.9 | $2,584.3 | -1.1% | 53.5% |
| Personal Care Products | $2,217.9 | $2,148.0 | +3.3% | 46.5% |
Personal Care (+3.3%) is outpacing Household (-1.1%), reflecting growth in TheraBreath, Hero Cosmetics,
and Trojan. Household decline driven partly by VMS divestiture and Batiste softness.
Private Label Exposure
~5%
Down from ~12% post-VMS divestiture
2026 Organic Growth Guide
3-4%
Ex-VMS FY25 organic was ~2%
International Mix
18%
Peers at 40-60% -- significant runway
M&A Capacity
$5B+
1.5x levered, $1.2B annual FCF
Oligopoly Gate: CONDITIONAL PASS -- Niche Category Oligopolies
Collection of Niche #1/#2 Positions -- Passes in Select Categories, Not at Enterprise Level
CHD passes the oligopoly gate in select niche categories, not at the enterprise level.
The company is best understood as a "collection of niche oligopolies" rather than a single dominant franchise.
Clear passes: Baking soda (~90%+ share, near-monopoly), condoms (~70%+ share, dominant #1), acne patches (#1 with growing moat), dry shampoo (#1 with loyalty leadership).
Strong but contested: Laundry (#1 in wash loads at 14.5%, but competes against P&G Tide and Henkel Persil), mouthwash (#2 at 22% behind Listerine, aspirations for #1), TheraBreath oral care expansion (only 12% household penetration vs. 65% category -- huge runway but unproven at scale).
Key distinction: The competitive moats are strongest in categories where total addressable markets are relatively small. In the larger TAM categories (laundry ~$12B, oral care ~$11.4B), CHD is credible but not dominant -- competing against much larger CPG companies with deeper pockets.
Clear passes: Baking soda (~90%+ share, near-monopoly), condoms (~70%+ share, dominant #1), acne patches (#1 with growing moat), dry shampoo (#1 with loyalty leadership).
Strong but contested: Laundry (#1 in wash loads at 14.5%, but competes against P&G Tide and Henkel Persil), mouthwash (#2 at 22% behind Listerine, aspirations for #1), TheraBreath oral care expansion (only 12% household penetration vs. 65% category -- huge runway but unproven at scale).
Key distinction: The competitive moats are strongest in categories where total addressable markets are relatively small. In the larger TAM categories (laundry ~$12B, oral care ~$11.4B), CHD is credible but not dominant -- competing against much larger CPG companies with deeper pockets.
Brand-Level Market Position
| Brand | Category | Est. US Share | Position | TAM |
|---|---|---|---|---|
| Arm & Hammer | Baking Soda | ~90%+ | Near-monopoly | ~$1B |
| Trojan | Condoms | ~70%+ | Dominant #1 | ~$600-700M |
| TheraBreath | Mouthwash | ~22% | Record #2 | US oral care ~$11.4B |
| Hero Cosmetics | Acne / Patches | ~19% | #1 acne brand | ~$650M (global patches) |
| Batiste | Dry Shampoo | ~15-20% | #1 (losing share) | ~$3-4B (global) |
| Arm & Hammer | Laundry (liquid) | 14.5% | Record #1 wash loads | US laundry ~$12B |
| Arm & Hammer | Cat Litter | Strong | Strong #2 | US cat litter ~$5-6B |
| OxiClean | Laundry Additives | Leader | #1 in additives | Sub-segment of laundry |
| Arm & Hammer | Laundry Sheets | Leader | ~2x next competitor | Emerging sub-segment |
Green-highlighted rows indicate near-monopoly/dominant positions. Share data from company filings
and management commentary. Trojan US condom TAM growing at ~8% CAGR.
Theme 1: Portfolio Reshaping (Tailwind: STRONG)
VMS Divestiture Removes Weakest Position -- Private Label Down From ~12% to ~5% -- Focused Portfolio
The 2025 divestiture of Vitafusion/L'il Critters (VMS) was strategically sound.
The gummy vitamin category (~$7.3B global TAM, ~8.5% CAGR) was attractive, but CHD was losing share
to private label. The divestiture accomplished three things:
(1) Removed the weakest category position from the portfolio.
(2) Reduced private label exposure from ~12% to ~5%, dramatically improving portfolio quality.
(3) Concentrated the business on brands where CHD holds #1 or #2 positions with defensible moats.
Additionally, Spinbrush, Flawless, and Showerheads were divested or shut down -- non-core, low-growth brands that diluted the portfolio. Organic growth ex-VMS was ~2% in FY2025 vs. 0.7% reported, and the 2026 guide of 3-4% organic reflects the cleaner portfolio.
(1) Removed the weakest category position from the portfolio.
(2) Reduced private label exposure from ~12% to ~5%, dramatically improving portfolio quality.
(3) Concentrated the business on brands where CHD holds #1 or #2 positions with defensible moats.
Additionally, Spinbrush, Flawless, and Showerheads were divested or shut down -- non-core, low-growth brands that diluted the portfolio. Organic growth ex-VMS was ~2% in FY2025 vs. 0.7% reported, and the 2026 guide of 3-4% organic reflects the cleaner portfolio.
Theme 2: Value Tier Positioning in Laundry (Tailwind: MODERATE)
A&H Laundry Share
14.5%
Record share -- #1 in wash loads
US Laundry TAM
~$12B
Large category, competitive
A&H $2B-to-$3B Aspiration
Multi-Year
Laundry sheets + continued liquid gains
Consumer downtrading benefits Arm & Hammer value positioning in laundry. Record 14.5% share in 2025
came during a period of elevated promotions and weak consumer confidence. Arm & Hammer is #1 in
laundry sheets (~2x the next competitor) -- an emerging sub-segment with growth potential.
Caveat: This is a competitive oligopoly. P&G (Tide), Henkel (Persil), and private label all compete aggressively. Value tier growth is positive for A&H but margins can compress during promotional periods. The $2B-to-$3B aspiration is a multi-year build, not a near-term catalyst.
Caveat: This is a competitive oligopoly. P&G (Tide), Henkel (Persil), and private label all compete aggressively. Value tier growth is positive for A&H but margins can compress during promotional periods. The $2B-to-$3B aspiration is a multi-year build, not a near-term catalyst.
Theme 3: Oral Care Expansion via TheraBreath (Tailwind: STRONG)
12% Household Penetration vs. 65% Category -- Massive Whitespace -- Record 22% Mouthwash Share
TheraBreath is arguably the highest-upside brand in the CHD portfolio. At just 12%
household penetration vs. 65% for the oral care category, there is massive whitespace to
fill. The brand reached a record 22% mouthwash share in 2025, up from a much lower base, and is
now the #2 mouthwash brand behind Listerine.
The TAM expansion opportunity is significant: entry into toothpaste (a ~$4B US category) would be a material growth driver. TheraBreath has strong brand equity in "clinical efficacy" positioning that translates well across oral care sub-categories.
Risk: Scaling from 12% to higher penetration in oral care means competing directly against J&J (Listerine) and P&G (Crest/Oral-B) -- companies with vastly larger marketing budgets and distribution muscle. The toothpaste opportunity is unproven at scale.
The TAM expansion opportunity is significant: entry into toothpaste (a ~$4B US category) would be a material growth driver. TheraBreath has strong brand equity in "clinical efficacy" positioning that translates well across oral care sub-categories.
Risk: Scaling from 12% to higher penetration in oral care means competing directly against J&J (Listerine) and P&G (Crest/Oral-B) -- companies with vastly larger marketing budgets and distribution muscle. The toothpaste opportunity is unproven at scale.
Theme 4: Hero Cosmetics Lifecycle Expansion (Tailwind: MODERATE)
Hero Acne Share
~19%
#1 acne brand, growing 3x category
Category Penetration
~1/3
Significant room to expand
Global Acne Patch TAM
~$650M
Growing rapidly, Hero is #1
Hero Cosmetics is growing at 3x the acne category rate and is the #1 acne brand with ~19%
share. The brand is expanding beyond patches into the full acne lifecycle -- cleanse, treat, protect,
restore. With only ~1/3 category penetration, there is meaningful runway remaining.
The international expansion opportunity is also significant: Hero, TheraBreath, and Touchland are all being deployed internationally, leveraging CHD distribution infrastructure built for Arm & Hammer.
The international expansion opportunity is also significant: Hero, TheraBreath, and Touchland are all being deployed internationally, leveraging CHD distribution infrastructure built for Arm & Hammer.
Theme 5: International Under-Penetration (Tailwind: MODERATE)
18% International vs. 40-60% for Most Multinationals -- +5.4% YoY Growth in FY2025
At 18% of sales from international markets vs. 40-60% for most multinational CPG companies, CHD has
a meaningful runway for geographic expansion. International grew +5.4% in FY2025, the fastest-growing
segment.
Recent acquisitions (Hero Cosmetics, TheraBreath, Touchland) are brands with strong international appeal that are being expanded rapidly across global markets. The acquisitive model remains intact with 1.5x leverage, $1.2B annual FCF, and $5B+ capacity for deals.
Recent acquisitions (Hero Cosmetics, TheraBreath, Touchland) are brands with strong international appeal that are being expanded rapidly across global markets. The acquisitive model remains intact with 1.5x leverage, $1.2B annual FCF, and $5B+ capacity for deals.
Headwind 1: Niche TAMs Limit Absolute Upside (Moderate Negative)
Dominant Categories Are Individually Small -- Baking Soda ~$1B, Condoms ~$700M, Patches ~$650M
The categories where CHD holds near-monopoly or dominant positions are individually small.
Baking soda (~$1B TAM), condoms (~$600-700M), acne patches (~$650M global), and dry shampoo
(~$3-4B global) are defensible but limit the absolute dollar upside from share gains.
In the larger TAM categories -- laundry (~$12B) and oral care (~$11.4B) -- CHD is a credible competitor but not dominant. Reaching dominant share in these categories would require displacing P&G and J&J, which is unlikely. The Arm & Hammer $2B-to-$3B aspiration is a multi-year build and represents the ceiling, not the base case.
In the larger TAM categories -- laundry (~$12B) and oral care (~$11.4B) -- CHD is a credible competitor but not dominant. Reaching dominant share in these categories would require displacing P&G and J&J, which is unlikely. The Arm & Hammer $2B-to-$3B aspiration is a multi-year build and represents the ceiling, not the base case.
Headwind 2: Batiste Losing Share (Moderate Negative)
Down ~2.5 Share Points in 2025 -- Still #1 but Momentum Is Negative
Batiste remains the #1 dry shampoo brand but lost ~2.5 share points in 2025. Management acknowledged
the brand "didn't have the year we wanted." While the dry shampoo category itself is growing (~$3-4B
global TAM), Batiste is ceding ground to competitors. This is a yellow flag -- share losses in a
growth category suggest either competitive intensity or brand fatigue that needs to be monitored.
Headwind 3: No Exposure to High-Growth Secular Themes (Structural)
Unlike some staples peers with health/wellness or clean-label mega-trends, CHD has no exposure to
high-growth secular themes. The company is a steady niche compounder -- not a "big theme" stock.
Category growth rates across the portfolio are moderate (2-8% CAGR), which supports consistent but
not exceptional organic growth. This is reflected in the 3-4% organic growth guide for 2026.
The consumer staples sector rotation risk (beta of 0.47) also means CHD will underperform in risk-on environments. This is a feature for defensive portfolios but a headwind for absolute returns.
The consumer staples sector rotation risk (beta of 0.47) also means CHD will underperform in risk-on environments. This is a feature for defensive portfolios but a headwind for absolute returns.
Score Rationale
| Factor | Impact | Notes |
|---|---|---|
| Oligopoly positions in niches | +2.0 | Condoms ~70%+, baking soda ~90%+, acne patches #1, dry shampoo #1 |
| TAM size of dominant categories | -1.0 | Individually small; laundry/oral care are large but CHD is less dominant there |
| Category growth rates | 0 | Moderate 2-8% across categories; not high-growth secular themes |
| Market share trajectory | +0.5 | Gaining in laundry, oral care, acne; losing in dry shampoo (Batiste) |
| Portfolio reshaping | +0.5 | VMS divestiture was value-creative; private label exposure cut from 12% to 5% |
| Organic growth potential | 0 | 3-4% guide is solid but not exceptional for staples |
| International runway | +0.5 | 18% international vs. 40-60% for peers -- meaningfully under-penetrated |
| Thematic relevance | -0.5 | Niche compounder, not a "big theme" stock; no mega-trend exposure |
6.5/10 — CHD scores a 6.5 reflecting
solidly above-average but not exceptional thematic positioning.
The score is anchored by strong niche oligopoly positions:
(a) Dominant niches. Near-monopoly in baking soda (~90%+), dominant #1 in condoms (~70%+), and #1 positions in acne patches, dry shampoo, laundry sheets, and laundry additives. These positions have durable competitive moats and support pricing power.
(b) Portfolio quality improvement. The VMS divestiture reduced private label exposure from ~12% to ~5% and concentrated the business on brands where CHD holds defensible #1/#2 positions. The 2026 organic growth guide of 3-4% reflects the higher-quality portfolio.
(c) Growth optionality. TheraBreath (12% household penetration vs. 65% category), Hero Cosmetics (growing 3x category), and international expansion (18% vs. 40-60% peers) provide meaningful avenues for growth beyond the base case.
Why 6.5 and not 7+: The dominant positions are in individually small TAMs -- the categories where CHD is most defensible are also the smallest. In the large categories (laundry, oral care), CHD is a credible but not dominant player competing against P&G and J&J. Batiste is losing share (-2.5 pts in 2025). There is no exposure to high-growth secular mega-trends -- the thematic story is steady compounding, not transformational growth. Overall organic growth of 3-4% is solid but modest for a company trading at 24.7x forward earnings.
The score is anchored by strong niche oligopoly positions:
(a) Dominant niches. Near-monopoly in baking soda (~90%+), dominant #1 in condoms (~70%+), and #1 positions in acne patches, dry shampoo, laundry sheets, and laundry additives. These positions have durable competitive moats and support pricing power.
(b) Portfolio quality improvement. The VMS divestiture reduced private label exposure from ~12% to ~5% and concentrated the business on brands where CHD holds defensible #1/#2 positions. The 2026 organic growth guide of 3-4% reflects the higher-quality portfolio.
(c) Growth optionality. TheraBreath (12% household penetration vs. 65% category), Hero Cosmetics (growing 3x category), and international expansion (18% vs. 40-60% peers) provide meaningful avenues for growth beyond the base case.
Why 6.5 and not 7+: The dominant positions are in individually small TAMs -- the categories where CHD is most defensible are also the smallest. In the large categories (laundry, oral care), CHD is a credible but not dominant player competing against P&G and J&J. Batiste is losing share (-2.5 pts in 2025). There is no exposure to high-growth secular mega-trends -- the thematic story is steady compounding, not transformational growth. Overall organic growth of 3-4% is solid but modest for a company trading at 24.7x forward earnings.
Data sourced from Daloopa, Church & Dwight FY2025 earnings calls, and third-party market research as of April 2026.